Market cap
$1,175 Mln
Recently Viewed
Clear All$18.76
$0.16
(0.86%)
As on 29-Apr-2026 11:39EDT
Market cap
$1,175 Mln
Revenue (TTM)
$23 Mln
P/E Ratio
--
P/B Ratio
0
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$0 Mln
ROE
-0.3 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
0
Debt to Equity
-0.1
Book Value
$--
EPS
$-1.2
Face value
--
Shares outstanding
53,403,173
CFO
$-180.21 Mln
EBITDA
$-253.51 Mln
Net Profit
$-278.92 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Akoustis Technologies (AKTS)
| -- | 23.5 | -8.5 | -- | 87.4 | 8.8 | 23.1 |
|
BSE Sensex
| -8.5 | 5.3 | -5.9 | -3.4 | 8.2 | 9.3 | 11.7 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|---|---|---|---|---|---|---|---|
|
Akoustis Technologies (AKTS)
| -70.4 | -57.8 | -45.4 | 52.9 | 61.0 | -20.1 | 6.0 |
|
S&P Small-Cap 600
| 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 | 11.7 |
|
BSE Sensex
| 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Akoustis Technologies (AKTS)
|
18.8 | 1,175.2 | 6.5 | -63.7 | -186.6 | 54.5 | -- | 0.0 |
| 87.7 | 8,150.8 | 1,442.1 | 107.6 | 10.2 | 12.5 | 77.2 | 9.1 | |
| 364.4 | 14,725.8 | 1,798.8 | 148.4 | 6.6 | 11.6 | 100.3 | 10.7 | |
| 146.5 | 12,596.6 | 455.7 | -38.2 | -9.6 | -7.9 | -- | 17.2 | |
| 206.7 | 7,713.0 | 3,738.3 | 312.8 | 11.1 | 16.7 | 26 | 4.0 | |
| 387.0 | 10,244.5 | 2,386.3 | -71.7 | 1.6 | -3 | -- | 4.2 | |
| 251.5 | 9,207.3 | 1,114.1 | 187.4 | 20.6 | 29.7 | 49.3 | 13.8 | |
| 204.8 | 14,209.7 | 5,934.5 | 279.5 | 11.8 | 4.3 | 50.7 | 2.1 | |
| 244.3 | 12,410.9 | 471.7 | 136.7 | 20.8 | 19.8 | 91.8 | 16.5 | |
| 300.1 | 15,436.3 | 23,510.9 | 640.2 | 5.3 | 12.8 | 24.4 | 3.1 |
Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company's lead product candidate includes... [225Ac]Ac-AKY-1189, a miniprotein radioconjugate platform which is in ongoing Phase 1b clinical trial for the treatment of Nectin-4 expressing solid tumors, including locally advanced or metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervical cancer; and [225Ac]Ac-AKY-2519 to deliver 225Ac to B7-H3 (CD276) expressing tumors, including prostate, lung and other solid tumors. It has license and collaboration agreements with Protein Innovation, Inc., TRIUMF Innovations, Inc., and Eli Lilly. The company was formerly known as HotKnot Therapeutics, Inc. and changed its name to Aktis Oncology, Inc. in April 2020. Aktis Oncology, Inc. was incorporated in 2020 and is headquartered in Boston, Massachusetts. Read more
Founder, President, CEO & Director
Mr. Jeffrey B. Shealy
Founder, President, CEO & Director
Mr. Jeffrey B. Shealy
Headquarters
Boston, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Akoustis Technologies Inc (AKTS) is $18.76 (NASDAQ) as of 29-Apr-2026 11:39 EDT. Akoustis Technologies Inc (AKTS) has given a return of 87.41% in the last 3 years.
Since, TTM earnings of Akoustis Technologies Inc (AKTS) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
--
|
--
|
|
2024
|
-0.04
|
-0.02
|
|
2024
|
--
|
--
|
|
2023
|
-2.13
|
-1.32
|
|
2023
|
--
|
--
|
The 52-week high and low of Akoustis Technologies Inc (AKTS) are Rs 23.36 and Rs 14.72 as of 29-Apr-2026.
Akoustis Technologies Inc (AKTS) has a market capitalisation of $ 1,175 Mln as on 24-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Akoustis Technologies Inc (AKTS), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.